Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort
Background Refractory cardiogenic shock (CS) remains associated with unacceptably high mortality despite advances in intensive-care and coronary intervention strategies. Percutaneous left ventricular support using Impella is widely used, yet real-world outcomes may differ substantially by underlying shock etiology and phenotype. Methods We performed a retrospective single-center cohort study of adults treated with Impella 2.5/CP for refractory CS over a 9-year period. Patients were classified as acute coronary syndrome (ACS), dilated cardiomyopathy (DCM)/myocarditis, severe aortic stenosis (AS), sepsis-associated CS, or other causes. Endpoints were all-cause in-hospital and 12-month mortality. Multivariable logistic regression adjusted for age, sex, lactate, vasoactive score, Impella type was conducted; a sensitivity model additionally included creatinine. Results Among 409 patients (mean age 69.99 ± 11.56 years; 75.6% male), ACS was the leading phenotype ( n = 269), followed by DCM/myocarditis ( n = 53), AS ( n = 32), sepsis-associated CS ( n = 36), and other causes ( n = 19). Impella CP was used in 227 patients (55.5%). Overall in-hospital mortality was 48.9% and differed across phenotypes, being highest in sepsis-associated CS (80.6%; chi-squared p < 0.001). Sepsis remained independently associated with in-hospital death after adjustment (adjusted odds ratio 4.65, 95% CI 2.03–12.07, p = 0.0006) for major confounders; finding was consistent after additional adjustment for creatinine (adjusted odds ratio 4.17, 95% CI 1.63–12.26, p = 0.0023). Major bleeding occurred in 14.9%, limb ischemia in 11.7%, pseudoaneurysm in 4.9%, and stroke in 1.0% of the patients. Twelve-month survival analysis also demonstrated phenotype-dependent patterns (log-rank p < 0.01). Conclusion In refractory CS treated with Impella outcomes are strongly phenotype-dependent. Sepsis-associated CS represents an extreme-risk phenotype with poor short- and long-term survival, suggesting phenotype-guided patient selection and prospective validation of escalation strategies.
Authors
- Christian Waechter (ORCID: https://orcid.org/0000-0003-1558-0696)
- Felix Ausbuettel (ORCID: https://orcid.org/0000-0003-0526-7989)
- Julian Kreutz (ORCID: https://orcid.org/0000-0001-9498-9558)
- Styliani Syntila (ORCID: https://orcid.org/0000-0001-5784-5563)
- Harald Schuett (ORCID: https://orcid.org/0000-0001-6804-7647)
- Harald Lapp (ORCID: https://orcid.org/0000-0002-7935-7808)
- Bjoern Goebel
- Birgit Markus (ORCID: https://orcid.org/0000-0002-0485-5722)
- Georgios Chatzis (ORCID: https://orcid.org/0000-0003-2258-0846)
- Bernhard Schieffer (ORCID: https://orcid.org/0000-0001-6677-7486)
- Kiarash Sassani
- Carlo-Federico Fichera (ORCID: https://orcid.org/0009-0003-6410-5784)
- Fares Kano
Institutions
- Philipps University of Marburg (DE)
- University of Münster (DE)
- Krankenhaus der Barmherzigen Brüder Trier (DE)
- Zentralklinik Bad Berka (DE)
- Kliniken des Landkreises Lörrach (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1007/s00392-026-03055-6
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00